论文部分内容阅读
目的:探讨以补脾肾化瘀毒法治疗多发性骨髓瘤(MM)患者溶骨病变的临床疗效。方法:将40例MM患者随机分成2组,对照组20例予M2方案化疗,中药组20例予中药毒结清口服液60mL/d,同时予M2方案化疗。以血钙和CRP水平下降,骨痛的缓解和生活质量改善为评价指标。结果:中药组和对照组治疗后骨痛症状评分均明显下降,与治疗前比较差异均有显著性意义(P<0.05);中药组生活质量总有效率为70%与对照组总有效率(45%)比较差异均有显著性意义(P<0.05);中药组治疗后血钙和CRP水平均明显下降(P<0.05),与对照组治疗后血钙和CRP水平比较差异也有显著性意义(P<0.05);对照组治疗后血钙水平较治疗前下降(P>0.05);对照组CRP水平明显下降,与治疗前比较差异有显著性意义(P<0.05)。结论:补脾肾化瘀毒法联合化疗能有效降低MM患者血钙和CRP水平,改善骨痛症状,提高生活质量。
Objective: To investigate the clinical efficacy of BuBu Ren Huayu Toxin in the treatment of osteolytic lesions in patients with multiple myeloma (MM). Methods: Forty patients with MM were randomly divided into two groups. Twenty patients in the control group received chemotherapy with M2 regimen. Twenty patients in the traditional Chinese medicine group received 60 mL / d of Chinese drug Tongjiqing oral solution and received M2 regimen. To calcium and CRP levels decreased, the relief of bone pain and quality of life as the evaluation index. Results: The score of pain symptom in Chinese medicine group and control group were significantly decreased after treatment (P <0.05), the total effective rate of quality of life in Chinese medicine group was 70% and the total effective rate in control group 45%, respectively) (P <0.05). The levels of serum calcium and CRP in Chinese medicine group were significantly decreased (P <0.05), and there was also significant difference between the control group and the control group (P <0.05). The level of serum calcium in the control group decreased after treatment (P> 0.05). The level of CRP in the control group decreased significantly compared with that before treatment (P <0.05). Conclusion: BuBu Huoxue Huayu method combined with chemotherapy can effectively reduce the level of serum calcium and CRP in patients with MM, improve the symptoms of bone pain and improve the quality of life.